Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

FDA drug approval process stories

Oct 14, 2026

FDA launches comprehensive review of rare disease drug approval process

The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.

Oct 14, 2026·5 sources
00
Sep 21, 2026

Grail's multi-cancer blood test shows no major safety concerns in FDA review

FDA staff reviewers found no major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers ahead of an advisory committee meeting. The company's shares surged 35% on the news.

Sep 21, 2026·3 sources
00
Sep 14, 2026

US, India launch initiatives to accelerate drug approval processes

The FDA is accepting applications for a pilot program to expedite drug testing in humans, while at least 19 US states have applied for a Medicaid drug-pricing experiment with international benchmarking. Separately, India's government is streamlining its drug approval process by allowing studies to begin after notifying regulators and cutting import license processing times in half.

Sep 14, 2026·3 sources
00
Sep 11, 2026

Scholar Rock receives first FDA approval for rare muscle-wasting disease therapy

The FDA approved Scholar Rock's therapy to treat a rare genetic condition causing muscle weakness, marking the first regulatory approval for the company and the first treatment for this specific disease.

Sep 11, 2026·2 sources
00

AstraZeneca's breast cancer pill fails late-stage trial after receiving FDA approval

AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.

Sep 11, 2026·4 sources
00
Sep 8, 2026

Study finds low rate of liver injury from avacopan amid FDA approval review

A U.S. study published in Arthritis & Rheumatology found that only 0.8% of patients treated with avacopan for ANCA-associated vasculitis developed drug-induced liver injury, with liver enzyme elevations being uncommon. The findings come as the FDA considers revoking approval for the drug following earlier safety concerns.

Sep 8, 2026·1 source
00
Sep 3, 2026

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.

Sep 3, 2026·5 sources
00
Sep 2, 2026

UniQure seeks FDA approval for Huntington's gene therapy after reversal

Dutch biotech UniQure submitted its Huntington's disease gene therapy to the FDA for approval after the agency reversed its earlier position on the experimental treatment, following an unusually turbulent development process.

Sep 2, 2026·3 sources
00
Aug 28, 2026

Priovant receives first FDA approval for targeted tablet in dermatomyositis

Priovant Therapeutics secured its first FDA approval for a targeted tablet treatment for dermatomyositis, a rare autoimmune disease affecting muscles and skin.

Aug 28, 2026·2 sources
00
Aug 26, 2026

RevMed's pancreatic cancer pill daraxonrasib wins FDA approval at $475,000 annual cost

Revolution Medicines' breakthrough pill targeting KRAS mutations in advanced pancreatic cancer received FDA approval, priced at over $475,000 per year. The drug nearly doubles survival in patients with this hard-to-treat cancer.

Aug 26, 2026·2 sources
00
Aug 24, 2026

Capricor's Duchenne muscular dystrophy cell therapy receives three-month FDA review extension

The FDA extended the review period for Capricor Therapeutics' experimental cell therapy deramiocel for Duchenne muscular dystrophy by three months after the company submitted new data with a refined indication.

Aug 24, 2026·2 sources
00
Jul 22, 2026

GSK receives FDA approval for Jideytro lung cancer drug

The FDA approved GSK's Jideytro for treating a form of lung cancer, nearly two months after the British drugmaker acquired the treatment as part of a $10.6 billion deal.

Jul 22, 2026·1 source
00

Johnson & Johnson receives FDA approval for soft tissue surgical robot

After more than a decade of development, J&J's robotic surgery device received FDA marketing authorization, allowing the healthcare conglomerate to enter the competitive surgical robotics market.

Jul 22, 2026·2 sources
00
Jul 16, 2026

Merck wins FDA approval for first oral PCSK9 cholesterol pill

Merck received FDA approval for its oral PCSK9 inhibitor cholesterol pill, the first of its kind, offering a more convenient alternative to existing injectable therapies for high-risk patients.

Jul 16, 2026·4 sources
00
May 4, 2026

FDA Rejects Promising Melanoma Drug RP1 Twice, Raising Concerns About Drug Approval Process

The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.

May 4, 2026·1 source
00
May 1, 2026

Axsome Wins FDA Approval for Alzheimer's Agitation Treatment

The FDA has approved Axsome's drug for treating agitation in Alzheimer's disease patients, marking a new therapeutic option for this challenging symptom.

May 1, 2026·1 source
00
Apr 22, 2026

Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.

Apr 22, 2026·1 source
00
Apr 8, 2026

Federal Judge Refuses to Block Mifepristone Mail Distribution, Orders FDA Review

A federal judge declined to block filling prescriptions for the abortion pill mifepristone by mail across the U.S., but ordered the FDA to complete a review of the practice.

Apr 8, 2026·1 source
00

Top claims

  • ▪In a white paper on the Rare Disease Framework Initiative, the FDA outlined plans to evaluate standards from pre-clinical trial engagement through post-marketing requirements.
  • ▪National Organization for Rare Disorders CEO Pam Gavin welcomed the FDA's focus on consistency across review divisions and inclusion of patient perspectives.
  • ▪The FDA highlighted existing programs including the Rare Disease Innovation Hub, CDER's ARC program, and the joint CDER-CBER RDEA pilot program.

People involved

Donald Trump

Subtopics

Drug Approval and Clinical Trials18Drug Policy, Pricing & Approval18New drug application (NDA) process17FDA drug approval5Pharma5Clinical trials4Cancer & Oncology3Healthcare Policy3Cancer Treatment & Therapies2Cancer Types2Drug pricing2Abortion access & policy1AI policy1AI regulation & lawsuits1Alzheimer’s & dementia1Autoimmune disease treatments1Biotech innovation1Cancer Prevention & Diagnosis1Cancer treatment1Cancer treatment breakthroughs1Cardiovascular health.1Cholesterol management1Clinical evaluation1Clinical Trial Design & Evaluation1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Ebola outbreak

85 stories

Iran War

209 stories

Russia-Ukraine war

136 stories